Compare LSPD & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LSPD | ODTX |
|---|---|---|
| Founded | 2005 | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2020 | 2025 |
| Metric | LSPD | ODTX |
|---|---|---|
| Price | $9.82 | $24.51 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $13.33 | N/A |
| AVG Volume (30 Days) | ★ 549.0K | 143.9K |
| Earning Date | 05-21-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.43 | N/A |
| Revenue Next Year | $10.94 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.83 | $15.10 |
| 52 Week High | $13.72 | $29.05 |
| Indicator | LSPD | ODTX |
|---|---|---|
| Relative Strength Index (RSI) | 39.95 | 54.10 |
| Support Level | $8.97 | $22.89 |
| Resistance Level | $9.93 | $28.00 |
| Average True Range (ATR) | 0.29 | 2.10 |
| MACD | -0.07 | -0.04 |
| Stochastic Oscillator | 2.25 | 34.96 |
Lightspeed Commerce Inc is a one-stop commerce platform providing its customers with the critical functionalities needed to engage with consumers, manage their operations, order their inventory, accept payments, and run their business. It has customers globally in over 100 countries, empowering single- and multi-location small and medium-sized businesses to compete in an omni-channel market environment by engaging with consumers across online, mobile, social, and physical channels. Its products are divided into retail, restaurant, and golf categories. Geographically, it operates in Canada, the United States, the United Kingdom, Switzerland, Germany, and Others with the majority of revenue deriving from Canada.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.